With a potential $2.9 billion on the line, Ionis Pharmaceuticals and AstraZeneca announced new results from the Phase III study of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The results will be presented Monday at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston.
Tag Archive for: eplontersen
Preliminary findings from the NEURO-TTRansform trial show Ionis Pharmaceuticals’ and AstraZeneca’s antisense candidate, eplontersen, is potentially a safe and effective treatment for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
